|Bid||27.81 x 1300|
|Ask||27.78 x 4000|
|Day's Range||27.53 - 27.83|
|52 Week Range||16.56 - 29.44|
|Beta (3Y Monthly)||0.87|
|PE Ratio (TTM)||79.15|
|Earnings Date||Nov 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||34.50|
At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of June 28. In this […]
Horizon Therapeutics plc (HZNP) announced today that it has been selected to FORTUNE Magazine’s 2019 “Best Medium Workplaces” list for the fourth consecutive year. Horizon ranked eighth out of 100 other medium sized companies. “We are honored that FORTUNE and Great Place to Work has named Horizon a 2019 Best Workplace,” said Timothy Walbert, chairman, president and chief executive officer, Horizon.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, if...
Horizon Therapeutics plc (HZNP) today announced it has initiated an open-label clinical trial evaluating the use of KRYSTEXXA® (pegloticase injection) in adults with chronic gout refractory to conventional therapies – also known as uncontrolled gout – who have undergone a kidney transplant to demonstrate that KRYSTEXXA may provide effective disease control without burdening the kidneys.
Here are four stocks positioned right at key technical breakout points. Horizon Therapeutics PLC (HZNP) climbed 92 cents to $28.20 on 2.3 million shares traded Tuesday, more than 1 1/2 times its average volume. The move, which came on no news from the drug maker targeting treatments for rare and rheumatic diseases, edged the stock out of a two-month sideways channel.
By Harry Boxer, TheTechTrader Here are four stocks positioned right at key technical breakout points. Horizon Therapeutics Public Limited Company (NASDAQ: HZNP ) climbed 92 cents to $28.20 on 2.3 million ...
Horizon Therapeutics plc today announced new data from the Phase 3 OPTIC confirmatory clinical trial showing that teprotumumab provided significant benefit on several devastating effects of active thyroid eye disease compared with placebo, including diplopia , quality of life and clinical activity score .
Today, in support of World Sight Day, Horizon Therapeutics plc (HZNP) and Prevent Blindness launched a campaign that brings together the voices of the thyroid eye disease (TED) community to educate the public on how TED can damage vision and encourage people who are living with TED to put their vision first by sharing their experiences, monitoring their symptoms and finding the right doctor. World Sight Day is an internationally recognized awareness day designed to focus attention on blindness and vision impairment.
Horizon Therapeutics plc (HZNP) announced today that its third-quarter 2019 financial results will be released on Wednesday, Nov. 6, 2019. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results. The live webcast and a replay may be accessed at http://ir.horizontherapeutics.com.
Additional results from the Phase 3 confirmatory clinical trial of teprotumumab, an investigational medicine being developed by Horizon Therapeutics plc, will be presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery 50th Anniversary 2019 Fall Scientific Symposium in San Francisco on Oct.
Horizon Therapeutics plc (HZNP) today announced that it has been named one of the top 100 adoption-friendly workplaces in the country by the Dave Thomas Foundation for Adoption, ranking number 56 overall and number 2 in the pharmaceutical category. The list recognizes organizations with the most robust adoption benefit programs, comparing financial reimbursement and paid leave offered to employees who adopt, based on a survey of organizations across the United States. “My adoptive father helped change the trajectory of my life,” said Timothy Walbert, chairman, president and chief executive officer, Horizon.
Pharmaceutical stocks slipped a single-digit percentage in the first nine months of 2019, well below their gain for 2018. Still, there are standout companies among the industry group.
Shares of pharmaceutical companies toppled Tuesday on reports the House of Representatives will release a plan that allows the federal government to negotiate drug prices in Medicare.
Horizon (HZNP) announces the FDA has accepted the Biologics License Application (BLA) for teprotumumab, for the treatment of active thyroid eye disease, and granted it Priority Review designation.
-- If Approved, Teprotumumab Would be the First FDA-Approved Medicine for this Vision-Threatening Disease --
Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chairman, President and CEO of Horizon Therapeutics Plc (30-Year Financial, Insider Trades) Timothy P Walbert (insider trades) sold 58,820 shares of HZNP on 08/22/2019 at an average price of $28 a share. Continue reading...
Horizon Therapeutics PLC (NASDAQ: HZNP ), an actively traded small-cap biotech, is poised for further upside in the near-term on its product strength, according to BMO Capital Markets. The Analyst Gary ...